- Home
- DCGO vs XFOR Comparison
DCGO vs XFOR Comparison
Compare DCGO & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCGO
- XFOR
- Stock Information
- Founded
- DCGO 2015
- XFOR 2014
- Country
- DCGO United States
- XFOR United States
- Employees
- DCGO N/A
- XFOR N/A
- Industry
- DCGO Managed Health Care
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DCGO Health Care
- XFOR Health Care
- Exchange
- DCGO Nasdaq
- XFOR Nasdaq
- Market Cap
- DCGO 138.7M
- XFOR 118.4M
- IPO Year
- DCGO N/A
- XFOR N/A
- Fundamental
- Price
- DCGO $1.57
- XFOR $1.98
- Analyst Decision
- DCGO Strong Buy
- XFOR Strong Buy
- Analyst Count
- DCGO 4
- XFOR 3
- Target Price
- DCGO $3.74
- XFOR $72.33
- AVG Volume (30 Days)
- DCGO 758.1K
- XFOR 463.8K
- Earning Date
- DCGO 08-06-2025
- XFOR 08-07-2025
- Dividend Yield
- DCGO N/A
- XFOR N/A
- EPS Growth
- DCGO N/A
- XFOR N/A
- EPS
- DCGO N/A
- XFOR 2.16
- Revenue
- DCGO $520,500,658.00
- XFOR $31,364,000.00
- Revenue This Year
- DCGO N/A
- XFOR $1,106.53
- Revenue Next Year
- DCGO $4.08
- XFOR N/A
- P/E Ratio
- DCGO N/A
- XFOR $0.91
- Revenue Growth
- DCGO N/A
- XFOR N/A
- 52 Week Low
- DCGO $1.23
- XFOR $1.81
- 52 Week High
- DCGO $5.68
- XFOR $26.96
- Technical
- Relative Strength Index (RSI)
- DCGO 47.49
- XFOR 31.08
- Support Level
- DCGO $1.48
- XFOR $1.81
- Resistance Level
- DCGO $1.70
- XFOR $2.98
- Average True Range (ATR)
- DCGO 0.11
- XFOR 0.24
- MACD
- DCGO 0.01
- XFOR -0.05
- Stochastic Oscillator
- DCGO 38.71
- XFOR 12.14
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.